ArticleFrontiers in medicine2025
Secukinumab treatment in a pediatric patient with corticosteroid-intolerant pyoderma gangrenosum: a case report.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyoderma gangrenosum (PG) is a rare, rapidly progressive, non-infectious neutrophilic dermatosis characterized by severely painful ulcers. Its pathogenesis may be attributed to genetic factors, autoimmune dysfunction, and neutrophil disorders. Interleukin-17 (IL-17) inhibitors can suppress neutrophil activity by blocking the IL-17/IL-23 axis, which has been documented to be effective in PG treatment. However, there is limited response rate of treatments with the use of IL-17 inhibitors for PG. Accordingly, the present study reports on a pediatric case of corticosteroid-intolerant pyoderma gangrenosum treated with the IL-17A inhibitor secukinumab, where the patient achieved significant improvement. This case underscores that secukinumab may be a promising therapeutic option for pediatric PG, offering valuable insights for clinical practice in managing such refractory cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.